



International Journal of Food and Allied Sciences, 2017, 1(1): 20-26 
 
International Journal of Food and 
 Allied Sciences 
ISSN: 2415-0290 (Print) 





Clostridium difficile is a gram positive, spore-forming, 
anaerobic bacilli and the most frequent perpetrator of 
nosocomial infections affecting the gastrointestinal 
tract (Salliet, 2010; Segarra-Newnham, 2007). 
Clostridium difficile infections (CDI) are a major 
burden to the U.S. health system, accruing costs of 
about 3.2 billion dollars every year and is associated 
with a high rate of morbidity and mortality, resulting in 
possible bowel perforation, sepsis, or death (Surawicz, 
Brandt & Binion, 2013; Leong & Zelenitsky, 2013). 
Risk factors for the disease include recent antibiotic use, 
proton-pump inhibitors or other acid-suppressive 
therapies, advanced age, and immunosuppression. 
Altered normal flora as a result of antibiotic treatment 
greatly increases risk of CDI, but paradoxically, 
antibiotics are also first-line therapy for treatment. 
Antibiotics are 80% effective for the first CDI episode; 
however as the gut microbiota becomes further 
disrupted, risk of CDI relapse rises. CDIs reoccur in 
approximately 20% of patients and multiple recurrences 
lead to an even greater risk of relapse at about 50-60% 
(Segarra-Newnham, 2007). Recurrences are thought to 
arise when spores surviving an antibiotic treatment 
course germinate and reinitiate disease in the absence of 
protective gut flora (Surawicz, Brandt & Binion, 2013). 
A novel theory to combat recurrences uses colonization 
resistance by introducing healthy bacteria into the gut to 
restore the normal flora and prevent C. difficile from 
obtaining essential nutrients and surviving (Leong & 
Zelenitsky, 2013). This theory has led us to 
experimental treatments such as probiotics and fecal 
microbial transplant (FMT), in which feces of a healthy 
donor are implanted into the gastrointestinal tract of the 
diseased patient via oral, nasal, or rectal routes. Even 
patients who have had only a single CDI episode have 
markedly different bacterial flora and less bacterial 
diversity compared healthy individuals which 
demonstrates the great need to identify an effective 
therapy for restoring normal gut flora in these patients 
(Na & Kelly, 2011). 
Probiotics are readily accessible to patients in stores and 
online, making them a mainstay of preventative therapy. 
Common products include single or multi-strain 
probiotic capsules, live culture probiotic beverages such 
as kombucha (fermented tea) or kefir, (fermented milk) 
as well as many food products like yogurts. Probiotics 
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provide benefits such as reinforcing the intestinal lining 
that acts as a barrier to invading organisms, enhancing 
the immune system, and increasing the growth and 
proliferation of the normal flora. (Surawicz, Brandt & 
Binion, 2013; Na & Kelly, 2011). 
Saccharomyces boulardii is a nonpathogenic yeast 
probiotic that has been studied in the treatment of 
recurrent CDI. S. boulardii produces a protease that 
cleaves C. difficile’s toxins as well as their 
corresponding membrane receptors on the host 
intestinal cells (Castagliuolo, Riegler, Valenick, 
LaMont & Pothoulakis, 1999). By this mechanism, 
even after re-growth, C. difficile cannot reinitiate 
disease because its toxins can no longer bind their 
receptors (Surawicz, et al. 2000). S. boulardii grows at 
body temperature of 37°C and reaches a high steady-
state concentration of 107 to 108 colony forming units in 
the colon in just a few days. The yeast is resistant to 
antibiotics, has a half-life of 2-5 days, and has been 
shown to clear the gastrointestinal tract after 
discontinuing use (McFarland, 2010). S. boulardii is 
readily available inexpensively for 0.21 USD/capsule as 
a generic product, or under the trade name Florastor® 
(Biocodex, France) in the United States as lyophilized 
(freeze-dried) capsules, which are stable at room 
temperature for over a year. S. boulardii-containing 
probiotic capsules with their low cost, ease of use, and 
desirable administration may have a role for patients 
with recurrent CDI, defined as at least one prior episode 
previously treated with antibiotics. 
In this literature review, relevant sources were 
identified through a literature search of PubMed (1962 
to February 2016), Cochrane Library (1990 to 2015), 
International Pharmaceutical Abstracts (2000 to 2015), 
and CINAHL (2001 to 2015) using the following 
keywords: Clostridium difficile, probiotic, recurrent, 
and Saccharomyces boulardii.  
Selection requirements included case reports, clinical 
studies, and meta-analyses utilizing S. boulardii-
containing probiotics in the treatment of recurrent CDI 
as the primary outcome. Inclusion criteria were human 
data and studies published in English. Excluded studies 
comprised antibiotic-associated diarrhea as the primary 
outcome or treatment of recurrent CDI as a secondary 
outcome. One study was excluded because probiotic 
efficacy was determined by measuring the 
concentration of probiotic in stool samples, a practice 
determined to be clinically irrelevant (Elmer, 
McFarland, Surawicz, Danko & Greenberg, 1999; Pillai 
& Nelson, 2008). However, the complete outcome data 
were included in with a later study (Surawicz, 2000). 
Studies reviewed comprised one case report, one 
experimental trial, two randomized controlled trials, 
and two meta-analyses. 
Literature Review:  
1.1 Case Reports  
A 1990 case report described a 67-year-old woman with 
multiple recurrences of CDI (Kimmey, Elmer, 
Surawicz, McFarland, 1990). Over the course of 38 
weeks the woman experienced 8 episodes of recurrent 
CDI treated with multiple vancomycin tapers. Shortly 
after her eighth CDI episode, S. boulardii was initiated, 
250 mg capsules two by mouth twice daily, 
concurrently with a vancomycin taper. One week later, 
vancomycin was stopped and S. boulardii was 
continued for 2 months and then tapered to one capsule 
twice daily for 10 days. Follow-ups at 10 and 18 months 
after discontinuing S. boulardii determined that she 
experienced no further recurrences. While case report 
results have limited applicability to larger populations, 
this report demonstrates S. boulardii as a potential 
adjunctive therapy for recurrent CDI. 
1.2 Experimental Trials 
Surawicz et al. performed an open trial in 1989 using S. 
boulardii adjunctively to vancomycin in 13 patients 
with recurrent CDI (average of 3.6 recurrences). 
Patients were given a combination of vancomycin 250 
mg orally four times daily for 10 days, plus S. boulardii 
2, 250 mg capsules twice daily started on day 5 of 
vancomycin treatment and continued for at least 30 
days. The rationale for starting S. boulardii after 5 days 
of vancomycin and continuing beyond antibiotic 
therapy was explained that S. boulardii efficacy may be 
dependent on the ability of vancomycin to first clear C. 
difficile from the GI tract, then allowing S. boulardii to 
protectively colonize. Success was defined as no 
recurrence of diarrhea (3 or more loose stools per day 
for at least 2 consecutive days) for the duration of S. 
boulardii treatment. Eleven of the thirteen patients 
(85%) reported no further recurrences within the 30 
days of receiving S. boulardii, while two (15%) failed 
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culture positive following treatment, so it is possible 
that the vancomycin never cleared C. difficile, 
compared to the 11 successfully treated patients of 
which 82% were cytotoxin negative (P<0.001) 
following treatment. Seven patients were contacted 
(range 2-150 days, median 6 days) after cessation of S. 
boulardii and reported no further recurrences. This 
study’s limitations included small patient population, 
lack of a control group or randomization to antibiotic 
groups, and the follow-up may not have been long 
enough to detect delayed recurrences. 
1.3 Randomized Controlled Trials  
A double-blind randomized placebo-controlled trial 
utilized S. boulardii in combination with antibiotics for 
64 patients with an initial episode of CDI and 60 with a 
recurrence (McFarland et al., 1999a). Patients received 
metronidazole or vancomycin (chosen by the physician) 
in combination with either placebo or S. boulardii (two 
250 mg capsules twice daily) started within 4 days of 
antibiotics and continued for 4 weeks with an additional 
4-week follow-up. Study drug failures were defined as 
presence of diarrhea, pseudomembranes, or a positive 
C. difficile assay. Of the 124 patients, 30 of 67 (44.8%) 
failed treatment on placebo whereas 15 of 57 (26.3%) 
failed treatment on S. boulardii (P=0.05). Multivariate 
analysis was performed and S. boulardii was shown to 
be significant in reducing recurrences in patients with a 
history of recurrences, (34.6% vs 64.7%, P=0.04) but 
not in patients presenting with their first CDI episode 
(19.3% vs 24.2%, P=0.86). Adverse reactions reported 
with S. boulardii were increased thirst (9%) and 
constipation (14%). This study suggests that S. 
boulardii may be useful following multiple CDI 
recurrences when the gut flora has been markedly 
altered. Limitations include that patients were not 
randomized to antibiotic groups and this study was 
underpowered to detect a significant difference in 
patients presenting with their first episode.  
An add-on study to the previous attempted to control for 
the dose and duration of antibiotics in combination with 
S. boulardii in hopes of defining a specific regimen for 
the treatment of recurrent CDI (McFarland et al., 
1999b). The study extracted results from a different 
trial, which randomized patients to three antibiotic 
groups: metronidazole (1 g/day), low-dose vancomycin 
(500 mg/day), and high-dose vancomycin (2 g/day), 
plus S. boulardii. Both the metronidazole and low-dose 
vancomycin groups were found to be nonsignificant in 
reducing recurrences compared to placebo, and 
therefore this sub-study focused only on patients 
prescribed high-dose vancomycin. Patients were 
prescribed a 10-day course of high-dose vancomycin (2 
g/day) plus placebo or S. boulardii two 250 mg capsules 
twice daily started on day 7 of vancomycin treatment 
and continued for 28 days. Study duration was 8 weeks 
with an additional 5-month follow-up. Of the 168 
patients, only 32 were prescribed high-dose 
vancomycin due to more severe infection and all had a 
history of at least one or more prior episode of CDI 
within the past year. Drug failures were defined as 
presentation of diarrhea after discontinuation of 
antibiotics and before the end of the 8-week study 
duration. Of the patients on high-dose vancomycin, 3 of 
18 (16.7%) taking S. boulardii experienced a relapse 
compared with 7 of 14 (50%) taking placebo (P=0.05). 
Four patients receiving placebo also experienced two 
relapses during the trial. During the 5-month follow-up, 
29 patients were successfully contacted and 3 of 13 
(23%) receiving placebo had recurred compared to zero 
patients taking S. boulardii. No adverse reactions were 
reported.  
Metronidazole and low-dose vancomycin were 
ineffective in the parent study possibly because C. 
difficile was not completely cleared. In these groups, 
41% of metronidazole patients and 11% of low-dose 
vancomycin patients remained C. difficile positive 
following antibiotic treatment, versus 100% clearance 
in the high-dose vancomycin group. It is also important 
to note that the 1000 mg/day dose of metronidazole may 
have been subtherapeutic. The Infectious Diseases 
Society of America recommends 1500 mg daily 
(Cohen, Gerding & Johnson, 2010). A limitation of this 
study was the small number of patients receiving high-
dose vancomycin due to randomization based on 
disease severity. As these patients presented with more 
severe disease, they may be inherently different from 
the other two antibiotic groups. The results may only be 
applicable to this specific patient population.  
1.4 Meta-analyses 
In a meta-analysis in 2006 of probiotics for prevention 
of antibiotic associated diarrhea and treatment of CDI, 
McFarland et al. evaluated 6 randomized controlled 
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antibiotic associated diarrhea. Of the 6 CDI studies, 2 
using S. boulardii reported a significant effect of  
Table 1: Summary of Studies Evaluating S. boulardii for the Treatment of Recurrent CDI 
Reference Study Type Patients Treatment/Duration Follow-up Results 
Kimmey (1990) Case Report n=1 S. boulardii: 2x250 mg caps twice 
daily x 2 months – then tapered to 1 
capsule twice daily x 10 days 
Antibiotics: vancomycin taper (dose 




Surawicz (1989) Experimental 
Trial 
n=13 S. boulardii: 2x250 mg caps twice 
daily started on day 5 of 
vancomycin, continued for 30 days 
Antibiotics: vancomycin 250 mg 
four times daily x 10 days  








(64 pts with an 
initial episode, 
60 with a 
recurrence) 
S. boulardii: 2x250 mg caps twice 
daily started within 4 days of 
antibiotics x 4 weeks or placebo 
Antibiotics: metronidazole or 
vancomycin according to prescriber 
discretion (dose, duration not 
specified) 
4 weeks S. boulardii in 
initial episode: 
(19.3% vs 24.2%, 
P=0.86) 
S. boulardii in 
history of 
recurrences:  
(34.6% vs 64.7%, 
P=0.04)  







S. boulardii: 2x250 mg caps twice 
daily started on day 7 of vancomycin 
x 28 days or placebo 
Antibiotics: metronidazole (1 g/day), 
low-dose vancomycin (500 mg/day), 




























S. boulardii or placebo: 44% of 
patients. Other studies included 
different strains 
 
Antibiotics: varied among trials 
Varied Probiotics in 
frequency of 
CDI: (RR 0.59, 
95% CI 0.41-
0.85, P=0.005) 





Pillai (2008) Meta-analysis n=328  
(initial or 
recurrent CDI) 
S. boulardii or placebo: 89% of 
patients. Other studies included 
different strains 
Antibiotics: varied among trials 
Varied S. boulardii in 
initial or 
recurrent disease: 
(RR 0.59, 95% CI 
0.35-0.98) 
 
probiotics versus placebo in reducing the incidence of 
recurrent CDI, while 4 studies using non-S. boulardii 
probiotics determined there was no difference. Both 
studies showing significance are discussed above and of 
note, these two studies and this meta-analysis were 
written by the same author. Combined efficacy for the 
6 studies showed that probiotics are significantly 
effective for decreasing risk of CDI recurrences (RR for 
CDI 0.59 [95% CI 0.41-0.85] P=0.005). S. boulardii 
was the only probiotic strain that exhibited significant 
efficacy for reducing recurrences. Adverse effects 
reported were thirst and constipation with S. boulardii 
and no cases of fungemia, bacteremia, or other serious 
events were reported in the 31 trials and over 3,000 
patients included. The authors concluded that probiotics 
are effective for the treatment of CDI.  
Conversely, a Cochrane review determined that there is 
insufficient evidence to recommend probiotics as an 
adjunct to antibiotics for the treatment of CDI (Pillai & 
Nelson, 2008). Four randomized controlled trials of 
probiotics in combination with antibiotics were 
evaluated, two of which are discussed above, while the 
other two used probiotics other than S. boulardii 
(Surawicz, 2000; McFarland, 1994; Wullt, Haglslatt, 
Odenholt, 2003; Lawrence, Korzenik, Mudy, 2005). 
The authors determined clinical heterogeneity among 
studies in terms of antibiotic use and defining recurrent 
CDI were such that no current recommendation can be 
made. The authors also stated that the trials analyzed 
were likely too small and lacked the power to detect a 
significant difference. 
Discussion:   
The 2013 American College of Gastroenterology 
guidelines for CDI conclude there is only weak 
evidence for S. boulardii in recurrent CDI, but fecal 
microbiota transplant (FMT) may be considered after a 
third recurrence and failure of a pulsed vancomycin 
regimen. The 2010 SHEA/IDSA guidelines for CDI 
reference the McFarland et al. clinical trial stating that 
S. boulardii in combination with vancomycin appears to 
decrease recurrences. However, they expressed about 
possible fungemia in immunocompromised patients 
(Cohen, Gerding, Johnson, 2010). The authors conclude 
that there is no compelling evidence for probiotics in the 
treatment of CDI recurrences.  
Although S. boulardii is traditionally safe and 
nonpathogenic, probiotics are not completely benign 
and the possibility of fungemia exists. Some major risk 
factors for bloodstream infections include severe 
immunosuppression and prematurity in infants, while 
minor risk factors include presence of a central venous 
catheter, an impaired intestinal barrier (diarrhea or 
inflammation), concomitant administration of a broad-
spectrum antibiotic that does not cover the probiotic, 
and administration of the probiotic via a J-tube.2 Despite 
this, overall risk of bacteremia or fungemia from 
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and there is no evidence that risk of infection from a 
probiotic is any greater than risk from a commensal 
organism (Hedge, Strain, Heins, Farver, 2008). 
Additionally, it is believed that bloodstream infection 
from one of these organisms is a marker of extremely 
bad health and poor prognosis. In general, the above 
studies in patients cited to be at increased risk of 
fungemia demonstrate only minor adverse reactions 
associated with S. boulardii and no serious adverse 
events were reported, although it is important to note 
that most excluded severely immunocompromised 
patients.  
Conclusion: 
Efficacy data for S. boulardii in recurrent CDI were 
limited and the studies analyzed used small patient 
populations with varying follow-up, which may have 
concealed further recurrences. Durations of antibiotics 
and probiotics among studies also varied making a 
precise recommendation on when and how to use S. 
boulardii in recurrent CDI difficult.  
Nonetheless, the studies examined generally showed 
benefit in patients taking the probiotic with minimal 
risk, demonstrating that it might be a reasonable option 
to consider in some patients. S. boulardii may be of 
benefit in patients who have suffered from multiple 
recurrences, having exhausted antibiotic avenues such 
as tapers, and are aesthetically or financially hesitant to 
undergo invasive FMT, as this is currently the only 
guideline-recommended option. If a patient is willing to 
attempt a trial of S. boulardii and is unsuccessful 
resulting in subsequent recurrences, FMT should be 
strongly considered. In those with severe 
immunosuppression or a central venous catheter, 
probiotics should be used cautiously or alternative 
treatment should be selected.  
S. boulardii is readily available, inexpensive, desirable 
to consumers, and poses little risk in individuals without 
severe immunosuppression. Due to the wide array of 
probiotic products available on the market, products 
with regulatory quality control programs should be 
selected if possible. As an adjunct treatment to 
antibiotics, S. boulardii may be an affordable and 
accessible option for trial in patients with recurrent CDI, 
refractory to multiple antibiotic regimens, before 
resorting to undergo invasive FMT. 
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